| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues-Royalty | NaN | 0 | NaN | NaN |
| Revenues | NaN | 13,858 | NaN | NaN |
| Cost of revenues | NaN | 2,388 | NaN | NaN |
| Clinical Product Candidates | NaN | 9,640 | NaN | NaN |
| Clinical Product Manufacturing | NaN | 5,534 | NaN | NaN |
| Personnel Related Expenses Excluding Stock Based Compensation | NaN | 3,744 | NaN | NaN |
| Stock Based Compensation | NaN | 767 | NaN | NaN |
| Depreciation And Amortization | NaN | 434 | NaN | NaN |
| Other | NaN | 1,592 | NaN | NaN |
| Total research and development expenses | NaN | 21,711 | NaN | NaN |
| Personnel Related Expenses Excluding Stock Based Compensation | NaN | 1,165 | NaN | NaN |
| Stock Based Compensation | NaN | 1,315 | NaN | NaN |
| Professional And Consultant Fees | NaN | 1,789 | NaN | NaN |
| Other | NaN | 965 | NaN | NaN |
| Total general and administrative expenses | NaN | 5,234 | NaN | NaN |
| Total costs and operating expenses | NaN | 29,333 | NaN | NaN |
| Other segment income | NaN | 1,292 | NaN | NaN |
| Income tax expense (benefit) | NaN | 1,103 | NaN | NaN |
| Net loss | -23,272 | -18,106 | -61,515 | NaN |
| Depreciation and amortization | 459 | 2,897 | 1,614 | NaN |
| Stock-based compensation | 1,210 | 2,082 | 9,719 | NaN |
| Non-cash operating lease expense | 228 | 219 | 605 | NaN |
| Accretion of discount on marketable debt securities | 239 | 375 | 2,585 | NaN |
| Prepaid expenses and other current assets | -694 | -1,569 | 1,308 | NaN |
| Accounts payable | -5,896 | 1,129 | 4,897 | NaN |
| Accrued expenses and other current liabilities | 1,232 | 552 | -3,375 | NaN |
| Operating lease liabilities | -396 | -380 | -1,070 | NaN |
| Other | 20 | 14 | 57 | NaN |
| Net cash used in operating activities | -26,000 | -10,427 | -53,075 | NaN |
| Redemption of marketable debt securities | 27,361 | 16,261 | 149,610 | NaN |
| Purchase of marketable debt securities | 10,992 | 0 | 107,005 | NaN |
| Purchase of property and equipment | NaN | 0 | 9 | NaN |
| Net cash provided by investing activities | 16,369 | 16,261 | 42,596 | NaN |
| Proceeds from issuance of common stock and pre-funded warrants in private placement, net of offering costs | 0 | 0 | 2 | NaN |
| Proceeds from issuance of common stock pursuant to atm program, net of offering costs | NaN | 0 | NaN | NaN |
| Tax withholding payments related to net settlement of restricted common stock | 25 | 71 | 77 | NaN |
| Proceeds from the exercise of stock options | NaN | 632 | NaN | NaN |
| Proceeds from issuance of common stock under espp | NaN | 108 | NaN | NaN |
| Net cash used in financing activities | -25 | 669 | -75 | NaN |
| Restricted cash | NaN | NaN | NaN | 1,472 |
| Net decrease in cash, cash equivalents and restricted cash | -9,656 | 6,503 | -10,554 | NaN |
| Cash and cash equivalents | NaN | NaN | NaN | 10,733 |
| Cash, cash equivalents and restricted cash at beginning of year | 16,894 | 10,391 | 20,945 | NaN |
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows | NaN | NaN | NaN | 12,205 |
| Cash, cash equivalents and restricted cash at end of period | 7,238 | 16,894 | 10,391 | NaN |
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)